• Wangkun Chen, Junchi Yu, and Suting Li.
• Department of Encephalopathy, Wuxi No. 2 Chinese Medicine Hospital, Jiangsu, China,Department of Internal Medicine, BinZhou Polytechnic, Shandong, China.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundPei Yuan Tong Nao (PYTN) capsules has been widely used for the treatment of cerebrovascular disease, including cerebral infarction. However, the mechanisms of action of PYTN capsule on cerebral infarction are ambiguous and unclear. We conducted a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of PYTN capsules for the treatment of cerebral infarction.MethodsA comprehensive search of several databases from 1966 to February 2022 will be conducted. The databases includes Ovid Medline In-Process & Other NonIndexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid PsycINFO, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Two authors independently performed the literature searching, data extraction, and quality evaluation. The risk of bias in each included study will be assessed utilizing the Cochrane Collaboration's risk of bias tool. The Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) will be used to analyze the data.ResultA synthesis of current evidence of PYTN capsules for cerebral infarction will be provided in this protocol.ConclusionThis review will provide more reliable references to help clinicians make decisions when dealing with cerebral infarction.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…